Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
A study of more than 1000 elderly patients has revealed that there are no links between statin medication and cognitive decline.
Researchers have identified a new fear pathway between the auditory cortex and the lateral amygdala in mice that may aid further research into fear-related conditions such as anxiety and post-traumatic stress disorder.
A research team have discovered a new mechanism by which elovanoids may protect retinal and brain cells against neurodegenerative diseases such as Alzheimer’s and age-related macular degeneration.
NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
A woman genetically predisposed to have early-onset autosomal dominant Alzheimer’s disease at the age of 40 did not display symptoms until her 70s. This has been linked to the presence of a rare gene variant termed APOE3ch.
Scientists have discovered that an artificial intelligence program, coupled with the chemical analysis of blood samples, could speed up brain tumor diagnosis.
A new therapeutic concept, which utilizes dynorphin-based gene therapy, has been developed and could suppress seizures at their site of origin and on demand.
A blood test that measures the amount of cfDNA has been indicated to be correlated with how patients will progress following a glioblastoma diagnosis.